Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

Opinion
Video

Panelists discuss how loading doses remain crucial for treatment-naive patients to achieve rapid disease control, while patients switching therapies may require modified approaches based on their prior treatment response and disease activity.

Current Time 0:00
Duration 7:12
Loaded: 0%
Stream Type LIVE
Remaining Time 7:12
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following:

    • How strictly do you adhere to the loading dose recommendations for new therapies in treatment-naive patients with neovascular age-related macular degeneration and diabetic macular edema?
    • How about for patients who are switching therapies?

    Newsletter

    Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

    Subscribe Now!
    Recent Videos
    (Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
    AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
    3 experts are featured in this series.
    Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
    Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
    Angiogenesis 2025: The global forecast for AI-driven home OCT
    3 experts are featured in this series.
    Perspectives on the Usefulness of Real-world Data
    3 experts are featured in this series.
    Safety Profile of New Therapies
    3 experts are featured in this series.
    Outcomes with Raricimab and Choosing Between the New Therapies
    3 experts are featured in this series.
    Faricimab Molecular Design and Role of Ang-2
    2 experts in this video
    Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
    3 experts are featured in this series.
    Patient Selection for Aflibercept 8 mg
    2 experts in this video
    Adverse Events of the Port Delivery System and Addressing Challenges With Adoption
    Related Content
    An image which shows a translucent head, with the eye, brain and optic nerve highlighted. Concept for brain-eye neurology neuroinflammation connection. Image credit: ©jitendra jadhav – stock.adobe.com

    Journal of Neuroinflammation publishes data on Eleva’s lead retinal asset CPV-104

    Sydney M Crago
    April 16th 2025
    Article

    In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

    PHOTON Results and Their Relation to DME Patients in Your Practice

    PHOTON Results and Their Relation to DME Patients in Your Practice

    July 25th 2024
    Podcast

    John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

    An image of two older adults on a bench. Concept image for giant cell arteritis and vision loss from sudden ocular change in vasculitis. Image credit: ©C Coetzee/peopleimages.com – stock.adobe.com

    European Commission expands upadacitinib (Rinvoq) indication to include giant cell arteritis

    Hattie Hayes
    April 8th 2025
    Article

    Patients with GCA, an autoimmune disease, are at risk for sudden vision loss which can be permanent

    PULSAR Results and Their Relation to nAMD Patients in Your Practice

    PULSAR Results and Their Relation to nAMD Patients in Your Practice

    July 24th 2024
    Podcast

    John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

    An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

    Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

    Martin David Harp
    April 2nd 2025
    Article

    Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

    A close-up of a doctor's face. The doctor wears PPE including a mask and safety goggles. Oncology and ophthalmology concept image. Image credit: ©H_Ko – stock.adobe.com

    New study investigates ocular involvement in multiple myeloma

    Lynda Charters
    April 1st 2025
    Article

    Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

    © 2025 MJH Life Sciences

    All rights reserved.